Pegdinetanib/CT-322 protein is a synthetic peptide chimera and a biological agent that inhibits Vascular endothelial growth factor (VEGF). In medicine, its main function is to inhibit the secretion of VEGF to tumor cells, thereby preventing the spread and growth of tumors to surrounding tissues.
Background of Pegdinetanib/CT-322
Pegdinetanib/CT-322 is a biological agent based on human antibodies. It is a tumor treatment drug jointly developed by Corning Inc. and Genentech Corporation. It is approved by FDA for the treatment of lung cancer and renal cell cancer. Its full name is Pegylated Recombinant Humanized Monoclonal Antibody to VEGF and its variants, and its structure is composed of two human peptide chains and two mouse peptide chains. It has high affinity and stability, which can effectively inhibit the activity of VEGF.
The Function of Pegdinetanib/CT-322
VEGF is an important growth factor closely related to regulating processes such as neovascularization and vascular permeability. During the process of tumor growth, tumor cells can secrete a large amount of VEGF to surrounding tissues, promoting the formation and growth of new blood vessels, and spreading and metastasis to distant areas. The function of Pegdinetanib/CT-322 is to inhibit the activity of VEGF and prevent its stimulating effect on tumor cells, thereby preventing the growth and diffusion of tumor cells.
Related Signaling Pathways of Pegdinetanib/CT-322
The VEGF signaling pathway is a complex biological response system that includes VEGF and related cell membrane receptors, intracellular signal transduction molecules, and many therapeutic targeting molecules of varying sizes. Pegdinetanib/CT-322 can inhibit the activity of VEGF and its related cell membrane receptors by binding to them, and prevent the participation of cytokines upstream of related signaling pathways, thereby hindering the growth and diffusion of tumor cells.
Pegdinetanib/CT-322 Related Diseases
Tumor is the main disease used by Pegdinetanib/CT-322. It can be used to treat many kinds of tumors, such as lung cancer, renal cell carcinoma, breast cancer, gastrointestinal tumors, etc. Research data shows that the therapeutic effect of Pegdinetanib/CT-322 is superior to traditional chemotherapy regimens, which helps to improve the success rate and survival rate of tumor treatment.
Potential Applications of Pegdinetanib/CT-322 in Medicine
In addition to tumor treatment, Pegdinetanib/CT-322 can also be used to treat eye diseases, such as age-related Macular degeneration (AMD), which is a common senile eye disease and can lead to blindness. Research has shown that Pegdinetanib/CT-322 can inhibit the formation and growth of new blood vessels, thereby preventing further deterioration of AMD.
In addition, Pegdinetanib/CT-322 can also be used to treat various diseases caused by vascular abnormalities, such as diabetes retinopathy, stroke sequelae, etc. These diseases are closely related to vascular abnormalities. Pegdinetanib/CT-322 plays its therapeutic role by inhibiting the formation and growth of vascular abnormalities.
Pegdinetanib/CT-322 Related Investigational Drugs
In addition to Pegdinetanib/CT-322, there are also many VEGF inhibitors under development, such as RA101495, Aflibercept, Bevacizumab, etc. These drugs inhibit the activity of VEGF in different ways and can be used to treat various tumors and other vascular related diseases.
